Tag
Higher cumulative inotropic exposure during VA ECMO support in cardiogenic shock is associated with increased risk of ECMO weaning failure, mortality, arrhythmias, and delayed lactate clearance, highlighting the need for prospective trials
A pilot multicenter RCT comparing conservative vs liberal post-oxygenator oxygen targets during VA-ECMO for cardiogenic shock found the conservative approach difficult to maintain (target achieved 33% of time) and no difference in biomarker
A mediation analysis of the randomized ECLS‑SHOCK trial found that VA‑ECMO increased moderate–severe bleeding and vascular complications but these events did not statistically mediate 30‑day mortality in patients with acute myocardial infar
In the LEVOECMO randomized trial (n=205), early levosimendan did not reduce time to successful VA‑ECMO weaning or improve 60‑day mortality versus placebo; ventricular arrhythmias were more frequent with levosimendan.
A multicenter study reveals that 30% of adult VA-ECMO patients survive 12 months without new disability, with most disability developing within the first 6 months. Functional independence and employment improve by 12 months post-ECMO.
